ABSTRACT

**Introduction:** Adalimumab is a recombinant fully-human monoclonal immunoglobulin (IgG1) antibody utilized in the treatment of Crohn’s disease. Unfortunately no clinical or genetic markers exist to predict response to anti-tumor necrosis factor-alpha (TNF) therapy. The aim of this study was to evaluate the association between selected genes involved in cytokine regulation and response to adalimumab treatment in Crohn’s disease.

**Methods:** Twenty-four patients with Crohn’s disease either naïve (n=8) or had lost response or were unable to tolerate the chimeric anti-TNF antibody infliximab (n=16) were enrolled in the study. Patients were genotyped for main polymorphisms in NOD2, CD14 and TLR4 genes. Response to adalimumab treatment was defined as a decrease of Crohn’s disease activity index of at least 100 points or a closure of at least 50% of fistulas in case of fistulizing Crohn’s disease.

**Results:** Overall, 75% of patients did respond to treatment. However, no statistically significant association was found between any of the genotypes and the response to adalimumab.

**Conclusions:** In our small study group no association between the studied polymorphisms and response to adalimumab was apparent. Systematic studies to search for genetic markers of response to anti-TNF therapy are necessary.

**Key words:** Crohn’s disease. Genotypes. Adalimumab.

INTRODUCTION

Although recent studies have identified several genes linked to Crohn’s Disease (CD), the discovery of NOD2/CARD15 gene in 2001 by two independent groups (1,2) was the first CD susceptibility gene. NOD2 single nucleotide polymorphisms (SNPs) also have been associated with different clinical forms of the disease in a number of populations, including some studies in Spain (3,4). In our country a great heterogeneity among different regions has been described (5), even in a study performed in Asturias not association between NOD2 and CD was showed (6).

Toll-like receptors (TLRs) play a key role in the recognition of bacteria, virus and other pathogens. Variants of toll-like receptor-4 (TLR4) and CD14 genes (components of the lipopolysaccharide receptor complex) may also be relevant to Crohn’s disease susceptibility, as has been revealed by recent phenotype-genotype TLR-4 and CD14 mutation analyses (7-10).

Adalimumab (ADA) is a recombinant fully-human monoclonal immunoglobulin (IgG1) antibody utilized in the treatment of CD, among other inflammatory and immune disorders (11). The mechanism of action of ADA relies on neutralizing the biological function of tumor necrosis factor (TNFα) by blocking its interaction with TNF receptors (12). Compared to other treatments of reference such as infliximab, the subcutaneous administration of ADA offers patients an advantage by not having to depend on infusion centers. Additionally, treatment with ADA is an option on those patients who have lost response to or are intolerant to infliximab (13-15). According to clinical trials, this represents a third of the patients under infliximab during the first year of therapy (16).

No predictive factors of response to ADA have been identified as yet (17). We hypothesized that mutations in
CD susceptibility genes might be involved in response to treatment. ADA suppresses nuclear factor κB (NF-κB) through the inhibition of TNF-α, whereas NOD2/CARD15 activates NF-κB thus potentially favoring the production of TNF-α. In this way, NOD2 mutations may be involved in altered activity of the NF-κB gene which in turn could be related to differential response to biologic treatment. TLR4 and its transmembrane co-receptor CD14 signaling pathway results in the activation of NF-κB and triggers pro-inflammatory cytokine production.

The objective of the present study is to assess whether SNPs in NOD2 (R702W, G908R and 1007fs), in TLR4 (Asp299Gly) and in CD14 are predictive factors for differential clinical response to treatment with ADA.

METHODS

Twenty-four adult patients with CD attending the University Hospital of Santiago who had been treated with ADA were enrolled in the study. Inclusion criteria were: either naïve to ADA (n = 8) or had lost response or were unable to tolerate infliximab (n=16). All patients were stratified on the basis of age, years of disease, gender, and disease evolution according to the Montreal classification (18). From each patient, 15 ml of venous blood was collected in EDTA tubes. Samples were kept at -20ºC until DNA extraction. Genotype analysis for the three main variants of the NOD2 gene associated with CD: R702W, G908R and 1007fs (also called SNP8 (dbSNP ID rs2066845)), SNP12 (rs2066845) and SNP13 (rs2066847), respectively) as well as for CD14 (rs2569190) and TLR4 (rs4986790) was conducted for all patients. Genotyping was performed by polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP). Following PCR, the amplicons were digested and products were separated on a 2% (G908R, CD14 -260 allele A) and the reverse primer 5'-TCACCTCCCACCTCTCT-3'. The PCR product was digested with NcoI.

The objective of the present study is to assess whether SNPs in NOD2 (R702W, G908R and 1007fs), in TLR4 (Asp299Gly) and in CD14 are predictive factors for differential clinical response to treatment with ADA.

The objective of the present study is to assess whether SNPs in NOD2 (R702W, G908R and 1007fs), in TLR4 (Asp299Gly) and in CD14 are predictive factors for differential clinical response to treatment with ADA.

RESULTS

Among a group of 165 CD patients, a total of 24 patients (mean age 40.5 years, mean duration of disease 10 years, female 66.6%) received treatment with ADA. Eight patients were naïve to ADA, and 16 were intolerant to or had lost response to infliximab. A total of 33% of patients had luminal inflammatory CD (Montreal classification B1) and 66% had fistulizing CD (Montreal classification B3). Clinical data and demographic characteristics of the population are summarized in table 1.

As for treatment response, 75% of patients responded to ADA, 16.7% lost response to treatment and 12.5% terminated treatment due to adverse events. No differences in response were observed according to disease evolution (inflammatory or fistulizing CD), nonetheless a higher percentage of naïve patients achieved response to treatment in comparison to non-naïve patients.

Six (25%) patients were carriers of at least one of the three NOD2 mutations. The TLR4 896 allele G was found in 4.2% of CD patients, whereas the CD14 -260 allele C was present in 62.4% of CD patients.

Response to treatment did not differ between patients with or without mutations in NOD2 (overall presence or any of the mutations separately), TLR4 896 and CD14 -260 (Fig. 1). Additionally, no differences were observed
with regard to adverse events or lost of response between patients who were carriers when compared with non-carriers of any of the studied polymorphisms (Table II).

**DISCUSSION**

Biological therapies have shown great efficacy in the treatment of CD particularly in severe cases and in patients who fail to respond to conventional therapies such as corticosteroids (22-24). Nonetheless, although most of the patients have a good response to treatment, not all patients show a benefit from biological therapies and some patients are refractory to these novel molecules. Unfortunately, despite several studies of potential predictors to clinical response, no gene variants predictive of biological therapy response have yet been identified.

In our study, we aimed to establish an association between mutations on CARD15, TLR4 and CD14 and response to ADA treatment. Our rational is based on the mechanism of action of newer biological therapies, such as infliximab and adalimumab, which depend on the suppression of the NF-κB system through inhibition of TNF-α. Because Nod2 activates NF-κB and potentially interacts with TNF-α production, mutations in these genes could result in an altered NF-κB activation. An evaluation at the genetic level could contribute to reveal the mechanism responsible for the therapeutic response of biological therapy seen in clinical practice (25).

Indeed, in rheumatoid arthritis, an association between certain genotypes and differential response to ADA has been reported. As an example, one study has shown that patients bearing the GGC haplotype of TNF gene (-238G/-308G/-857C) in a homozygous form showed low response rate to ADA treatment (26), whereas in another study, TNF -308 homozygous (G/G) patients showed better response than heterozygous (G/A) patients (27). In other studies the development of antibodies directed against adalimumab has been shown to be associated with interleukin- (IL)10 polymorphisms (28).

Regarding CD, in previous studies from Leuven (Belgium) three polymorphisms in apoptosis genes had been identified potentially influencing the response to infliximab in luminal and fistulizing CD patients. The strongest association was seen between the Fas ligand -843 TT genotype and non-response to infliximab (29,30). With respect to the genes we studied, two independent studies with a large number of patients also excluded NOD2 gene variants as predictors for response to infliximab (31,32).

### Table I. Demographic characteristics and clinical data

<table>
<thead>
<tr>
<th>Patients, n (%)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number</td>
<td>24</td>
</tr>
<tr>
<td>Gender (Males/Females)</td>
<td>8 (33.3)/16 (66.6)</td>
</tr>
<tr>
<td>Smokers (current or ex-smokers)</td>
<td>15 (62.5)</td>
</tr>
<tr>
<td>Age Range</td>
<td>26-58</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>40.5 ± 9.5</td>
</tr>
<tr>
<td>Family history of IBD</td>
<td>2 (8.3)</td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td></td>
</tr>
<tr>
<td>&lt; 40 years (A1)</td>
<td>23 (95.6)</td>
</tr>
<tr>
<td>&gt; 40 years (A2)</td>
<td>1 (4.2)</td>
</tr>
<tr>
<td>Disease evolution - Phenotype</td>
<td></td>
</tr>
<tr>
<td>Inflammatory (B1)</td>
<td>8 (33.3)</td>
</tr>
<tr>
<td>Strictureing (B2)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Penetrating (B3)</td>
<td>16 (66.6)</td>
</tr>
<tr>
<td>Disease location</td>
<td></td>
</tr>
<tr>
<td>Terminal ileum (L1)</td>
<td>9 (37.5)</td>
</tr>
<tr>
<td>Colon (L2)</td>
<td>3 (12.5)</td>
</tr>
<tr>
<td>Ileum-colon (L3)</td>
<td>12 (50.0)</td>
</tr>
<tr>
<td>Upper gastrointestinal tract (L4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Extraintestinal manifestations</td>
<td>12 (50.0)</td>
</tr>
</tbody>
</table>

*IBD: inflammatory bowel disease.*

### Table II. Percentage of patients carrying mutations in NOD2, TLR4 and CD14 who show loss of response or adverse reactions

<table>
<thead>
<tr>
<th>Loss of response</th>
<th>Adverse reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>NOD2</td>
<td>25</td>
</tr>
<tr>
<td>TLR4</td>
<td>0</td>
</tr>
<tr>
<td>CD14</td>
<td>75</td>
</tr>
</tbody>
</table>

Fig. 1. Percentage of patients carrying mutations in NOD2, TLR4 and NOD2 who show response to ADA treatment. No statistically significant differences of response were observed between genotypes.
Our study supports the results that have been reported in another study (n=16) which analyzed possible associations between response to ADA and NOD2 mutations, but in our study in a higher number of patients (33). Regarding potential influence of mutations in loss of response or development of adverse events, there are not specific studies about this setting and will be necessary a higher number of patients to extrapolate conclusions. Moreover, here we show for the first time, with the limitation of the number of patients, that there is no association between biologic treatment response and TLR4 and CD14 mutations.

Nonetheless, the low sample size of our population and the little number of patients with NOD2 or TLR4 mutations which may be related to the relative homogeneity of our population, may limit the extrapolation of our outcomes. Another limitation is that we also evaluated response and we have no data on remission.

In conclusion, in our Spanish Galician population response to ADA was not associated with CD susceptibility variants in the NOD2, TLR4 and CD14 genes. Subsequent studies in a larger and more heterogeneous population should be performed.

REFERENCES


